Prof. Catharina Svanborg appointed Chief Medical Officer of HAMLET Pharma, overseeing clinical trials

HAMLET Pharma has formally appointed Prof Catharina Svanborg, Chairman and founder of HAMLET Pharma, as Chief Medical Officer (CMO), to enable her to continue her involvement in research and drug development. Specifically, this step allows the company to ensure critical coordination and oversight of clinical trials and regulatory processes.

Prof Svanborg says, “Clinical trials are already underway at the University Hospital in Prague. The physicians there are committed and truly excited about the unique therapeutic potential of HAMLET Alpha1H. They share our wish to find new drugs that treat bladder cancer without side effects, and they are working diligently on the combined phase I/II protocol, to evaluate the effects of Alpha1H. It is vital for us to be able to offer dedicated guidance and support during this intensive period. That will be my first goal as CMO.”

HAMLET has been proven to kill over 40 types of cancers/tumors in the laboratory without harming healthy cells. The company chose to focus on bladder cancer in these clinical trials, based on the proven effectiveness of local instillations of HAMLET into patients with bladder cancer, as well as on the rapidly escalating number of bladder cancer patients worldwide, an additional 430,000 each year.1 In the EU alone, 118,000 new cases and 52,000 deaths were recorded in 2012, and the economic burden in the EU is estimated at EUR 4.9 billion per year.2 It is the most costly form of cancer.

As the physicians in Prague continue to recruit the 40 patients needed to evaluate the safety and efficacy of HAMLET Alpha1H, Prof Svanborg will ensure as CMO that both phases of the clinical trials run efficiently, so that Hamlet Pharma can move towards final regulatory approval and the next phases of drug development as swiftly as possible. “We are extremely optimistic about the progress to date,” says Mats Persson, CEO of HAMLET Pharma, “This may be a turning point not only for HAMLET Pharma, but for bladder cancer therapy.”

The company also announces the appointment of Olivia Coker-Decker, public relations consultant, to support international investor and media relations. “Based in Zurich, Ms. Coker-Decker brings multinational experience from both the medical and financial sectors. Now that the first clinical trials are underway, we will seek to expand our activity base, and she is well-positioned to support us with comprehensive communications in several key parts of the world,” says CMO Prof Svanborg.

 

For more information, please contact:

Olivia Coker-Decker
Investor & Public Relations
olivia.cokerdecker@hamletpharma.com
+41 79 109 94 69

 

References

1 https://www.ncbi.nlm.nih.gov/pubmed/27370177
2 https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5773684/

 

About HAMLET Pharma

HAMLET Pharma, listed on AktieTorget, develops drugs based on the unique tumoricidal protein-lipid complex, HAMLET, formed by two natural and harmless molecules found in breast milk. Development focuses on drugs, which will be used primarily for the treatment and prevention of cancer. HAMLET kills tumor cells, and has proven safe in proof-of-concept studies in animal models. HAMLET has shown a therapeutic effect on skin papillomas in a placebo-controlled clinical trial and injection of HAMLET into the bladders of patients with bladder cancer has caused the shedding of dead cancer cells. Phase I/II clinical trials in human patients with bladder cancer are currently underway. HAMLET is a registered trademark of HAMLET Pharma.